Total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within normal limits. (control by thyroid replacement therapy is acceptable.) Participants with T3, free T3 or free T4 abnormalities at screening who are asymptomatic can be eligible
History of other malignancy unless the subject has been disease-free for at least 3 years
History of prior malignancy unless disease free for > or equal to 12 months or considered surgically cured.
Any other cancer, unless the patient has been disease-free for ?5 years
Willing to be smoke-free for 7 days
Clinically disease-free after surgery
Disease-free interval =< 30 months
have had a progression-free and treatment-free interval of at least 12 months after completion of the last rituximab-containing treatment OR
Prior invasive malignancy (except non-melanoma skin cancer), unless disease-free for at least 3 years; no patient with a history of pelvic or hematologic malignancy is eligible, regardless of disease-free interval
Patients who have a history of another primary malignancy unless the patient has been disease free for >= 3 years
Thyroid Function: Total T3 or free T3, total T4 or free T4 and THS ? CTCAE Grade 2 abnormality.
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Previous diagnosis of invasive cancer from which the individual is NOT disease-free AND that has required treatment within the past 5 years, except for superficial skin, cervical cancer in-situ, well-differentiated thyroid or early stage prostate or bladder cancer (i.e., treatment with curative intent and long term disease-free expectations)
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Previous diagnosis of invasive cancer from which the individual is NOT disease-free AND that has required treatment within the past 5 years, except for superficial skin, cervical cancer in-situ, well-differentiated thyroid or early stage prostate or bladder cancer (i.e., treatment with curative intent and long term disease-free expectations)
Have a prior history of cancer other than MDS or myeloproliferative disorder, unless the subject has been free of the disease for ? 1 year prior to the start of study treatment.
Must have disease free status as determined by imaging within 4 weeks of dosing
History of another malignancy, unless the candidate has been disease-free for at least 5 years.
Previous diagnosis of invasive cancer from which the individual is NOT disease-free AND that has required treatment within the past 5 years, except for superficial skin, cervical cancer in-situ, well-differentiated thyroid or early stage prostate or bladder cancer (i.e., treatment with curative intent and long term disease-free expectations).
Patient has EITHER:\r\n* A Kattan nomogram predicted probability of being disease free 5 years after surgery of < 60%, OR\r\n* A Gleason sum >= 8
Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment and are considered free of disease
Patients who have been continuously disease-free for any solid tumor malignancy >3 years prior to the time of enrollment.
Similar condition with an expectation of > 95% five-year disease-free survival
Patients with a previous malignancy (other than the patients' known cancer) that were treated successfully and are disease-free for at least 3 years are allowed
Any other cancer from which the patient has been disease-free for 5 years
Disease-free
Any other cancer from which the subject has been disease-free for ?2 years
Any other cancer from which the subject has been disease-free for ?3 years
History of another malignancy in the previous 5 years, unless cured by surgery alone and continuously disease-free
Free of metastatic malignancy (other than MDS) for ?2 years
Eligible patients must be considered disease-free or have stable disease
Free of macro-metastatic disease
Free from significant psychiatric history
NON-CANCER PATIENT GROUP: Cancer-free
Be considered disease-free at baseline
Clinically cancer-free (no evidence of disease)
If patients have a history of malignancy other than melanoma or malignant brain tumor they must be disease-free (excluding primary cancer for metastatic patients) for >= 5 years at the time of enrollment
History of any malignancy (excluding primary cancer for metastatic patients) other than melanoma or malignant brain tumors for which the disease-free interval is < 5 years
Any other cancer from which the subject has been disease free for 3 years
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated expected curative outcome
History of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death;
Malignancies other than TNBC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)
Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
History of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or death
Malignancies other than head and neck cancer within 5 years prior to Day 1 of treatment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than UCa within 3 years prior to Day 0, with the exception of those with negligible risk of metastasis or death treated with expected curative outcome;
Concurrent malignancies other than BCC, other than those with negligible risk of metastases or death
Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1 except those with a negligible risk of metastasis or death
Active malignancies within 3 years except for those with a negligible risk of metastasis or death treated with expected curative outcome.
History of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
History of malignancy other than NSLCL within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
Malignancies other than SCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than NSCLC within 5 years prior to enrollment, except for those curatively treated with negligible risk of metastasis or death
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
Malignancies other than urothelial bladder cancer within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome or incidental prostate cancer
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
Active malignancies within the past 12 months except negligible risk of metastasis or death treated with expected curative outcome.
History of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death
Any other malignancies within 5 years except those with negligible risk of metastasis or death
Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death
Concurrent history of malignancy other than cervical cancer within 3 years of first planned dose of REGN2810, except for tumors with negligible risk of metastasis
Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.
Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
History of malignancy, including prior SCCHN primary tumors within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
Malignancies other than triple negative breast cancer (TNBC) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer)
Malignancies within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
Malignancies other than disease under study within 5 years prior to Day 1 of Cycle 1
Patients who have had chemotherapy (for other malignancies) within 3 years prior to registration.
Known additional malignancy that is active and/or progressive requiring treatment; subjects with other malignancies that have been definitively treated and who have been rendered disease free will be eligible.
Participant has a history of other malignancies within 2 years prior to study entry, with the exception of:
Patients with prior malignancies, including pelvic cancer, are eligible if they have been disease free for > 5 years; patients with prior in situ carcinomas are eligible provided there was complete removal
Malignancies other than TNBC within 5 years prior to randomisation)
Patients with prior invasive malignancies are allowed, provided they have been treated with definitive intent and have no evidence of active disease requiring treatment in the past 2 years
Has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the subject is to be disease free for at least 5 years. Subjects with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. Subjects will not be excluded for recurrent NMIBC, basal or squamous cell skin cancers, or noninvasive cancer of the cervix.
Participant has a history of other malignancies prior to study entry, with the exception of:
Concurrent malignancy or malignancy within 3 years prior to starting study drug, except\r\n* Malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse, or\r\n* Malignancies not requiring treatment (e.g., RAI stage 0 chronic lymphocytic leukemia [CLL])
Patients with a history of non-breast invasive malignancies are eligible if they have been disease-free for 1 or more years prior to entry into the study
Other invasive malignancies within past 5 years from date of registration
Disease free of other malignancies beside the ALL at the time of the study
Other invasive malignancies within the past 5 years from date of registration
Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible
No active secondary malignancy; patients with other prior malignancies will be included, provided they have been disease-free for at least five years
Malignancies other than disease under study are excluded, except for any other malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).
Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy > than 6 months prior to study entry
Subject has a prior history of malignancies other than AML unless the subject has been free of the disease for ? 5 years from first dose of lenalidomide.
Subject has a history of other malignancies .prior to study entry, with the exception of:
Malignancies other than disease under study within 5 years
Prior history of malignancies, other than MM, unless the subject has been free of the disease for ? 5 years with the exception of the following non-invasive malignancies:
Malignancies other than disease under study within 5 years prior to D1 of C1
Prior history of malignancies, (except MDS for AML subjects), unless the subject has been free of the disease for ? 2 years. However, subjects with the following history/concurrent conditions are allowed:
Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1
Prior history of malignancies other than DLBCL, unless the patient has been free of the disease for ?5 years prior to screening.
Prior history of malignancies, other than diffuse large B-cell lymphoma, unless the subject has been free of the disease for ? 5 years from the signing of the ICD. Exceptions to the ? 5 year time limit include history of the following:
Malignancies that are expected to alter life expectancy or may interfere with disease assessment. Patients with adequately treated non-melanoma skin cancer and patients with prior history of malignancy who have been disease free for more than 3 years are eligible.
For all other malignancies, the subject is eligible if they have undergone potentially curative therapy and they have been considered disease free for at least 5 years prior to Screening.
Disease-free of other malignancies
Prior history of malignancies, other than follicular or marginal zone lymphoma, unless the subject has been free of the disease for ? 5 years.
History of other malignancies, unless disease-free for ? 5 years.
History of prior or concomitant malignancies within 3 years of study start
Other malignancy within 5 years except for noninvasive malignancies
Patient has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the patient is to be disease free for at least 5 years. Patients with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease.
For all other malignancies, the subject is eligible if he/she has undergone potentially curative therapy and has been considered disease free for at least 3 years prior to Screening.
Patients with history of previously treated malignancies who do not have any evidence of disease for the last three years are allowed
Concomitant malignancies or previous malignancies within the last 3 years; exception: patients who have been disease-free for 3 years, patients with a history of completely resected non-melanoma skin cancer, and/or patients with indolent secondary malignancies, are eligible
Prior history of malignancies, other than MM, unless the patient has been free of the disease for ? 3 years. Exceptions include the following:
Patients with history of prior malignancies (with exception to non-melanoma skin cancer) are ineligible for this study, unless they are documented to be disease-free for at least 5 years
Concomitant malignancies or previous malignancies with less than 2 years disease-free interval at the time of enrollment
Prior history of malignancies, other than CLL, unless the subject has been free of the disease for ?3 years. Exceptions include the following:
Concurrent active malignancy other than non-melanoma skin cancers or carcinoma-in-situ of the cervix, or presence of myelodysplastic or myeloproliferative disease; patients with prior malignancies with a disease-free interval of >= 5 years are eligible; patients who have had prior malignancies within the past 5 years but are considered to be “cured” with a low likelihood of recurrence may be eligible at the discretion of the principal investigator
Prior history of malignancies, other than CLL, unless the subject has been free of the disease for ?5 years. Exceptions include the following:
History of prior or concomitant malignancies within 3 years of study start
If there is a history of prior malignancies other than those below, must be disease free for at least 5 years. Patients with malignancies listed below less than 5 years before study entry may be enrolled if they have received treatment resulting in complete resolution of the cancer and have no clinical, radiologic, or laboratory evidence of active/recurrent disease.
History of second malignancies with life expectancy of < 2 years or requirement of therapy that would confound study results. This does not include the following:
Concomitant malignancies or previous malignancies treated within the past 3 years. Exception: Patients who have been disease-free for 3 years, patients with a history of completely resected non-melanoma skin cancer, and/or patients with indolent secondary malignancies, are eligible.
Disease-free of other malignancies
Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of in situ malignancies
Other prior malignancies, except for cured or adequately treated malignancies for which there has been no evidence of activity for more than 5 years.
Prior history of malignancies, other than multiple myeloma, unless the patient has been free of the disease for ? 3 years. Exceptions include the following:
Patients with prior malignancies are excluded unless treated with curative intent and known to be free of disease for at least 2 years
History of previous malignancies unless the cancer was stage I or II and rendered free of disease more than 1 year
Prior history of malignancies, other than MDS (MYELODYSPLASTIC SYNDROMES), unless the subject has been free of the disease for ? 3 years. However, subjects with the following history/concurrent conditions are allowed:
Subjects with prior history of malignancies, other than aggressive R/R NHL, unless the subject has been free of the disease for ? 2 years with the exception of the following non-invasive malignancies:
If the patient is a survivor of a prior invasive cancer, all of the following criteria must apply: *Patient has undergone potentially curative therapy for all prior malignancies \r\n*No evidence of active/recurrent disease within 5 years
Patient has a history of other malignancies within the last 5 years
